Trials / Completed
CompletedNCT05309304
Cefazolin PK Study 3g vs 2g
Pharmacokinetic Study of Cefazolin 3 g/150 mL in Subjects Weighing Greater Than or Equal to 120 kg Versus Cefazolin 2 g/100 mL in Subjects Weighing Less Than 120 kg
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Baxter Healthcare Corporation · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
Study is to characterize the safety and tolerability of cefazolin after a single IV administration in healthy subjects in a 3 g/150 mL presentation to meet the increasing clinical need for the indication of perioperative prophylaxis in this patient population weighing greater than or equal to (≥) 120 kg.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cefazolin | Cefazolin Injection - 2 g/100 mL or 3 g/150 mL |
Timeline
- Start date
- 2022-02-14
- Primary completion
- 2022-08-30
- Completion
- 2022-08-30
- First posted
- 2022-04-04
- Last updated
- 2022-10-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05309304. Inclusion in this directory is not an endorsement.